

October 2022

Hot Tip: Medication Assisted Treatment (MAT) of Opioid Use Disorder

Your Healthy Blue patients on non-preferred medication products may experience a pharmacy claim rejection. To avoid additional steps or delays at the pharmacy, please consider prescribing preferred products whenever possible. *Clinical Criteria* may need to be met for certain preferred products. Coverage should be verified by reviewing the *Preferred Drug List* on the Healthy Blue provider website: <https://provider.healthybluenc.com>. The *Preferred Drug List* is subject to change monthly.

Therapeutic class	Preferred products	Non-preferred products ⁴
MAT for Opioid Use Disorder ¹	Buprenorphine-Naloxone SL tablet ^{2, 5} <i>Generic for Suboxone</i> Suboxone SL film ² Sublocade ³	Buprenorphine-Naloxone SL film ² <i>Generic for Suboxone</i> Buprenorphine SL tablet <i>Generic for Subutex</i> Lucemyra tablet Zubsolv tablet SL
Footnotes: 1. <i>Clinical Criteria</i> apply to all drugs in this class. 2. Maximum daily dose of 24 mg/day (Suboxone and buprenorphine/naloxone). For daily doses between 24 mg and up to 32 mg, a pharmacist may override the edit at point-of-sale after consulting the prescriber to determine the clinical need for the higher dose. 3. For coverage of Sublocade, must have a diagnosis of moderate to severe opioid use disorder and have initiated treatment with a transmucosal buprenorphine-containing product followed by a dose adjustment period for a minimum of seven days. 4. Trial and failure of Suboxone SL film or buprenorphine/naloxone SL tablet required for coverage of non-preferred options. 5. As of October 1, 2022, Buprenorphine-Naloxone SL tablet is preferred.		

If you have questions regarding this *Hot Tip*, please call Healthy Blue Provider Services at **844-594-5072**.

<https://provider.healthybluenc.com>